Immunicum AB :
* Announces fully underwritten rights issue of about 111 million Swedish crowns ($13.62 million)
* Will use proceeds to extend phase II-trial with new clinics in the US and to initiate clinical trials in melanoma in the US and in Sweden
* Rights issue, excluding overallotment option, comprises up to 5,040,000 ordinary shares at a price of 22 crowns per share
* Overallotment option is of about 20 million crowns
* Subscription period in rights issue will take place between May 30 and June 14
* Terms of rights issue constitute that one (1) new share is issued for every four (4) existing shares Source text for Eikon: Further company coverage: ($1 = 8.1473 Swedish crowns) (Gdynia Newsroom)
0 nhận xét:
Đăng nhận xét